News & Updates

Use of iptacopan along with supportive care results in significant reductions in proteinuria at 6 months in patients with C3 glomerulopathy (C3G), a rare and severe form of proliferative glomerulonephritis brought about by the dysregulation of alternative complement pathway (AP), as shown in the APPEAR-C3G study. It is also well tolerated and has a favourable safety profile.

New drug applications approved by US FDA as of 16-31 May 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with olezarsen in patients with hypertriglyceridemia and elevated cardiovascular risk results in substantial reductions in triglyceride, apolipoprotein B, and non–high-density lipoprotein cholesterol levels, while having no major safety signals, according to data from the phase IIb Bridge–TIMI 73a study.

Patients with IgA nephropathy (IgAN) who have been treated with atacicept continue to show improvement in disease status through 72 weeks, with consistent reductions in the key indicators of IgAN and the kidney function remaining stable, according to the open-label extension phase of the phase IIb ORIGIN study.

Race and renal function both influence maintenance warfarin dosing in a multi-ethnic Southeast Asian population, suggests a study in Singapore. Specifically, impaired renal function is associated with lower warfarin maintenance doses, while South Asians may require a larger dose than Chinese and Malays.

Infusing lidocaine into a disposable injectable cervical dilator helps reduce pain during the removal of an intrauterine device (IUD), especially when intrauterine manipulations are needed, according to a study.

In patients with stage II colon cancer, individuals with a right-sided colon cancer (RSCC) appear to have a better prognosis than those with a left-sided colon cancer (LSCC), reveals a recent study. Additionally, adjuvant chemotherapy (ACT) falls short of improving cause-specific survival (CSS) in patients with either RSCC or LSCC.